While the industry faced a third year of disruption, its 2022 growth closely reflects the pre-COVID average growth rate.

The company’s orthopedic sales grew in the mid-single-digits for FY 2Q23 on the strength of core spine and enabling technology in the U.S.

The company declined in the mid-teens for 3Q22 as it works through its transformation but sees unmet needs that enabling tech could address.

The company’s 3Q22 orthopedic revenue grew more than 20% but changes to viscosupplement reimbursement will be a headwind through 1H23.

This month’s chart examines the knee and hip replacement sales for the big four players from the beginning of 2019 through 3Q22.

We estimate the orthopedic market grew in the low single-digits as procedure volumes recovered across most categories.

The company grew below 1% in 3Q22 due to a difficult prior year comparison, supply chain headwinds and slowly recovering elective procedures.

The company grew more than 18% in 3Q22 and will benefit from substantial CMS fee increases in ASCs for 2023.

The company grew in high single-digits for 3Q22 on the strength of case volume recovery and its portfolio of procedural solutions.

The company grew by more than 52% in 3Q22, spurred by accelerating contributions from its direct sale force.